Skip to content

AFRICA MIDDLE EAST

This region consists of 45 countries and is the number one region in the Commercial Pharmaceuticals segment by revenue, mainly driven by South Africa. Across the multiple countries in the region, commercial and sales employees not only support well-established local brands, but also internationally recognised medicines, with both having strong brand equity attributes. The primary manufacturing site in the region is in Gqeberha, South Africa, which has manufacturing capabilities extending to steriles and biologicals that are extensive, niche and differentiated including high potency and hormonal solids, as well as vaccines and other state-of-the-art sterile capabilities. There are two further regional manufacturing sites in South Africa which are located in Cape Town and East London. Additional regional sites in Africa are in Ghana, Kenya and Tanzania.

Key Countries

Egypt
Kingdom of Saudi Arabia
South Africa
Tanzania
United Arab Emirates

KEY BRANDS

Brand Therapeutic category
Eltroxin Thyroid hormone replacement
Mybulen Analgesic anti-inflammatory
Solpadeine Analgesic anti-inflammatory
Stilpane Narcotic analgesic combinations
Trustan Anti-ulcerant

NUMBER OF PERMANENT EMPLOYEES

3 945

June 2022

3 866

June 2021

africa-middle-east

STATISTICS

Number of products launched:

25

(2021: 48)

Number of product recalls:

1

(2021: 3)

Average staff turnover:

13%

(2021: 16%)

Number of work-related fatalities:

Nil

(2021: Nil)

Sales representatives:

218

(2021: 242)

Revenue 2022
R’million
2021 (CER)
R’million
Change
%
Commercial Pharmaceuticals 8 403 8 633 (3)
Regional Brands 7 878 8 108 (3)
Sterile Focus Brands 525 525 0
Manufacturing 1 872 927 >100
FDF 1 662 671 >100
API Chemicals 210 256 (18)
Total 10 275 9 560 7

Note: Commercial Pharmaceuticals revenue is by customer geography and manufacturing revenue by place of manufacture

  • The South African private pharmaceutical sector was valued at R52,04 billion MAT** for the period ended June 2022.
  • Aspen is ranked as the number one pharmaceutical company in the South African private sector with a 9,40% share by value.
  • By 2025, Middle East & Africa (“MEA”) pharma market is collectively estimated to be USD56 billion, with UAE and Egypt contributing 24,0% and 17,4% respectively.
  • Middle East, North Africa & Turkey (“MENAT”) pharmaceutical market is expected to grow by 4,63% CAGR from 2021 – 2024, driven mainly by Turkey and Egypt.

* Sources: IQVIA TPM MAT** June 2022, IQVIA Middle East & Africa Pharmaceutical Market Insights – Released June 2022; Source: IQVIA May 2022 MAT.

** Moving annual total.

Scroll To Top